NCT00856908View on ClinicalTrials.gov

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Type II Diabetes
Interventions
DRUG

AZD1656

Tolerable dose given twice daily

DRUG

Placebo

Tolerable dose given twice daily

Trial Locations (1)

Unknown

Research Site, Chula Vista

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY